[A25-159] Selpercatinib (RET fusion-positive NSCLC, first line) - Benefit assessment according to § 35a Social Code Book V (expiry of the limitation period)

Last updated 24.03.2026

Project no.:
A25-159

Commission:
Commission awarded on 01.01.2026 by the Federal Joint Committee (G-BA).

Report type:
Dossier assessment

Status:
Commission work started

Department/Division:
Drug Assessment

Topic:
Cancer

Project no.	Title	Status
A25-71	Selpercatinib (RET mutant medullary thyroid cancer) – Benefit assessment according to §35a Social Code Book V	Commission completed
A24-63	Selpercatinib (solid tumours) - Benefit assessment according to § 35a Social Code Book V	Commission completed
A24-62	Selpercatinib (thyroid cancer) - Benefit assessment according to § 35a Social Code Book V	Commission completed
A22-106	Selpercatinib (thyroid cancer) – Benefit assessment according to §35a Social Code Book V	Commission completed
A22-65	Selpercatinib (advanced NSCLC with RET fusion) – Benefit assessment according to § 35a SGB V	Commission completed
A21-29	Selpercatinib (RET fusion-positive thyroid cancer) - Benefit assessment according to §35a Social Code Book V	Commission completed
A21-28	Selpercatinib (RET mutant medullary thyroid cancer) - Benefit assessment according to §35a Social Code Book V	Commission completed
A21-27	Selpercatinib (non-small cell lung cancer) - Benefit assessment according to §35a Social Code Book V	Commission completed

Contact

Press contact

+49 221 356850

presse@iqwig.de

Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.